Emerging Trends in Drug Discovery Services Industry

Overview of This Research Study:

The present investigation entailed a comprehensive utilization of secondary sources, directories, and databases to ascertain and gather crucial data for the appraisal of the worldwide drug discovery services industry. Key industry participants, subject-matter experts (SMEs), C-level executives of major market players, and industry consultants were among the many primary respondents with whom in-depth interviews were conducted in order to gather and validate crucial qualitative and quantitative data and evaluate the market's growth prospects. To get the ultimate market size, the projected worldwide market size from secondary research was triangulated using data from primary research.

Major Growth Boosting Factors:

The market for drug discovery services is expanding due to a number of factors, including rising R&D spending from biopharmaceutical and pharmaceutical companies, an increasing R&D pipeline that is necessitating more outsourcing of analytical testing, efforts to research orphan drugs and rare diseases, and the high cost of in-house drug development. In addition, participants in this market could anticipate development prospects from technical advancements, the launch of novel drug discovery methods, patent expiration, and the increasing demand from end users for specialized testing services.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=138732129

Factors Which May Hinder Growth:

Strict laws controlling the use of animals in drug research

Securing safety and efficacy is regulatory agencies' primary focus during the drug approval process. These methods greatly raise the expense of the medication development process for the finished product, even if they validate the quality of the items introduced to the market. The uptake of a specific treatment can be greatly impacted by this issue in places where emerging markets are price-sensitive. In addition, a number of laws (such GMP and GLP) that guarantee product quality typically raise manufacturing costs.

Projected Growth in Revenue Generation:

The global drug discovery services market in terms of revenue was estimated to be worth $20.6 billion in 2023 and is poised to reach $41.3 billion by 2028, growing at a CAGR of 14.9% from 2023 to 2028.

Regional Growth Prospects:

In terms of the drug discovery services market, the Asia Pacific region is projected to develop at the quickest rate in 2022.

Geographically speaking, there are five main regions that make up the drug discovery market: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The developing middle class, growing government spending on pharmaceutical R&D, expanding therapeutic area expertise, and the region's rapidly expanding pharmaceutical and biopharmaceutical industries are all expected to contribute to the Asia Pacific market's predicted highest growth during the forecast period.

Key Players:

The drug discovery services market is dominated by a few globally established players such as Laboratory Corporation of America Holdings (US), Charles River Laboratories International Inc. (US), WuXi AppTec (China), and Thermo Fisher Scientific Inc (US), among others, are the key service providers that provided drug discovery services in last few years. Major focus was given to the deals, expansions, and new service launches due to the changing requirements of pharmaceutical and biopharmaceutical companies, academic and research institutes, and other end users across the world.

Request Free Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=138732129

Recent Developments of Drug Discovery Services Industry:

# In February 2023, Charles River Laboratories (US) announced a multi-program agreement with Pioneering Medicines, an initiative of Flagship Pioneering (US), allowing access to its Logica AI platform to discover small-molecule drugs.

# In February 2023, Evotec SE (Germany) and Related Sciences (US) expanded their partnership for an integrated multi-target drug discovery agreement. The two companies aimed to select, discover, and develop precisely targeted medicines for unmet patient needs.

# In January 2023, Charles River Laboratories (US) acquired SAMDI Tech, Inc. (US), which offers label-free HTS solutions for drug discovery research. The acquisition offered CRL expertise in label-free HTS MS platforms and created a comprehensive library of drug discovery solutions.

# In April 2022, Charles River Laboratories (US) and Valo Health, a data-driven AI company, launched Logica, an AI-powered drug discovery services.

Dental Labs: Newer Trends to Revolutionize Global Dentistry

Overview of This Research Study:

In order to find and gather data for the study, this research project made considerable use of secondary sources, directories, and databases (including D&B Hoovers, Bloomberg Businessweek, and Factiva). A number of industry experts from both the core and associated industries, as well as preferred manufacturers, distributors, suppliers, service providers, and technology developers, served as primary sources. Standard and certification bodies from businesses and organizations associated with every link in the value chain of this industry were also considered primary sources.

Major Growth Boosting Factors:

The geriatric population's rapid growth and the resulting rise in the prevalence of edentulism, technologically advanced solutions' development, the rise in dental tourism in emerging markets, the rising incidence of periodontal diseases and dental caries, the growing outsourcing of customization, and the growing number of dental laboratories investing in CAD/CAM technologies are the main factors driving this market's growth. There are significant development prospects shown by the rising demand for cosmetic dental operations.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223694318

Factors Which May Hinder Growth:

However, the high cost of dental supplies and equipment, the rising expense of dental procedures, and the difficulty in obtaining medical reimbursement policies are the main obstacles that are anticipated to impede market expansion. Two of the biggest issues facing the market are the pricing pressures that leading companies are under and the lack of qualified workers.

Projected Growth in Revenue Generation:

The global dental laboratories market In terms of revenue was estimated to be worth $35.0 billion in 2022 and is poised to reach $46.5 billion by 2027, growing at a CAGR of 5.9% from 2022 to 2027.

Regional Growth Prospects:

Over the course of the projection period, the dental labs industry in APAC is expected to develop at the fastest rate.

In the Asia-Pacific region, dental laboratories accounted for almost 30% of the global market. The APAC market is expanding due to a number of factors, such as an aging population, a rise in dental tourism, a development in dental laboratories, and an increase in the outsourcing of various industrial services to the region. UN estimates indicate that 727 million individuals globally will be 65 years of age or older by 2020. There will be 1.5 billion older persons on the earth by 2050.

Dental lab product demand is expected to rise because this population is more prone to experience tooth loss and conditions like cavities and gum disease. The industry is also influenced by customer adoption of cutting-edge technology and need for improved aesthetics.

Key Players:

Prominent players in the dental laboratories market are Dentsply Sirona, Inc. (US), Envista Holdings Corporation (US), 3M Company (US), GC Corporation (Japan), Mitsui Chemicals (Japan), Planmeca Group (Finland), BEGO GmbH & Co, KG (Germany), Ivoclar Vivadent (Liechtenstein), VOCO GmbH (Germany), Shofu Dental Corporation (Japan), VITA Zahnfabrik H. Rauter GmbH & Co. KG (Germany), Kuraray Noritake Dental Inc. (Japan), Amann Girrbach AG (Austria), Schütz Dental GmbH (Germany), Nakanishi Inc. (Japan), COLTENE Holding AG (Switzerland), Institut Straumann AG (Switzerland), A-dec Inc. (US). Stratasys (US and Israel), 3D Systems (US), Formlabs (US), Roland DG Corporation (Japan), SHINING 3D (US), and Zirkonzahn (US).

Request Free Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=223694318

Recent Developments of Dental Laboratories Industry:

# National Dentex Corporation Acquires Dental Services of Tennessee: National Dentex Corporation, a leading national network of dental laboratories, announced in February 2021 that it has acquired Dental Services of Tennessee (DST). The acquisition will expand National Dentex’s footprint in the Southeast region of the United States and add new capabilities to its product portfolio.

# Glidewell Acquires Florida-based Dental Lab: Glidewell Laboratories, one of the world’s largest integrated dental companies, announced in March 2021 that it has acquired Citrus Dental Lab, a full-service dental laboratory based in Florida.

# 3M Acquires Dental Lab Technology Provider Digital Dental: In April 2021, 3M announced that it has acquired Digital Dental, a developer and provider of software and hardware solutions for dental laboratories and practices. The acquisition will enable 3M to offer an expanded suite of dental lab technology solutions and expand its reach in the dental lab market.

# Patterson Dental Acquires Dental Lab Equipment Manufacturer DMD Solutions: Patterson Dental announced in April 2021 that it has acquired DMD Solutions, a leading manufacturer of dental laboratory equipment. The acquisition will enable Patterson to expand its portfolio of dental lab solutions and provide customers with a more comprehensive range of products and services.

Healthcare IT: Future Growth Prospects for Key Players

Overview of This Study:

The present investigation entailed a comprehensive utilization of primary and secondary materials. To determine segmentation types, industry trends, key players, the competitive landscape of the market, and important market dynamics, including drivers, constraints, opportunities, challenges, and key player strategies, a variety of industry-affecting factors were examined.

Global Growth Driving Factors:

Government mandates and support for HCIT solutions, together with the potential presented by growing healthcare markets, are the main drivers of market growth. Nonetheless, it is anticipated that the development of this sector would be somewhat constrained by the lack of IT infrastructure in poorer nations and opposition from conventional healthcare providers.

Projected Surge in Revenue Generation:

The global healthcare IT market in terms of revenue was estimated to be worth $394.6 billion in 2022 and is poised to reach $974.5 billion by 2027, growing at a CAGR of 19.8% from 2022 to 2027.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=252

Leading Players:

Prominent players in the healthcare IT market include Optum, Inc. (US), Cerner Corporation (US), Cognizant (US), Change Healthcare (US), Koninklijke Philips (Netherlands), Epic Systems Corporation (US), Dell Technologies, Inc. (US), Allscripts Healthcare Solutions, Inc. (US), athenahealth (US), GE Healthcare (US), Oracle Corporation (US), Wipro Limited (India), IBM (US), eClinicalWorks (US), Infor (US), Conduent (US), Conifer Health Solutions, LLC (US), Nuance Communications, Inc. (US), 3M (US), SAS Institute, Inc. (US), Carestream Health (US), Inovalon (US), Practice Fusion, Inc. (US),  Intersystems Corporation (US), Tata Consultancy Services (India).

Different Growth Strategies Adopted by Them:

These include product launches, contracts, partnerships, mergers and acquisitions, and new product development activities to further expand their presence in the human microbiome market.

In 2021, Optum, Inc. (US) held a prominent position in the healthcare IT industry. Healthcare payers, providers, employers, the government, and life science firms can all benefit from Optum, Inc.'s HCIT solutions. OptumHealth, OptumInsight, and OptumRx are the three business segments through which the corporation principally conducts business. The OptumHealth segment offers health financial services, wellness & consumer engagement, care management, and care delivery. Organizations in the healthcare sector can obtain software and information products from the OptumInsight category, including clinical documentation solutions, advisory consulting services, and business process outsourcing. OptumRx offers services and solutions to the pharmaceutical industry. The corporation has offices across the globe and invests USD 6.4 billion yearly in technology and innovation. It is well-known in the US, Australia, the UK, Canada, Brazil, Singapore, and India.

Cerner Corporation (US) is a global provider of HCIT solutions. The company offers a range of products and services such as medical device integration solutions, document management, imaging solutions, professional services, remote hosting, HCIT solutions, and other welfare and health services. Licensed Software, Technology Resale, Subscriptions, Professional Services, Managed Services, Support and Maintenance, and Reimbursed Travel are the seven key sectors through which the corporation offers these solutions. Hospitals, solo practitioner practices, healthcare providers, individual consumers, employer groups, and healthcare payers are among the company's primary end users.

In more than 35 countries, the company licenses its solutions to about 25,000 facilities, which include extended care facilities, employer sites, retail pharmacies, hospitals, physician practices, and ambulatory facilities (such as labs, behavioral health centers, cardiac facilities, radiology clinics, and surgery centers). Cerner Deutschland GmbH (Germany), Cerner France, Cerner Iberia S.L. (Spain), Cerner Ireland Ltd., and Cerner Limited (UK) are among the subsidiaries that the corporation uses to conduct business. By combining its PHM solutions with other healthcare IT solutions including telehealth, EHR, and patient portal platforms to provide virtual patient care, Cerner is continuously enhancing its product offerings.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=252

Geographical Growth Dynamics:

For the duration of the projection, Asia Pacific is anticipated to develop at the fastest rate.

Over the course of the projection period, the APAC market is anticipated to grow at the fastest rate. The APAC HCIT market is expanding due to a number of factors, including a sizable patient population—particularly in China and India—growing per capita income, increased healthcare industry investments by major participants in the market, and growing consumer awareness of cutting-edge technology.

Human Microbiome Market: Prominent Players, Globally..!

Overview of This Study:

In order to estimate the present size of the human microbiome market, this study includes four primary actions. A thorough investigation was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The following stage involved conducting primary research to confirm these conclusions, hypotheses, and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to assess the overall market size. Subsequently, methods for data triangulation and market breakdown were employed to estimate the market size of various segments.

Global Growth Driving Factors:

The market is predicted to rise at a rapid pace due to the growing demand for natural and holistic treatments as well as the booming need for individualized medication. Nonetheless, market expansion is anticipated to be somewhat constrained by our incomplete knowledge of microbial interactions.

Projected Surge in Revenue Generation:

With a predicted revenue of $0.3 billion in 2023 and a projected compound annual growth rate (CAGR) of 36.1% from 2023 to 2029, the worldwide human microbiome market is expected to reach $1.7 billion.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Leading Players:

The market for human microbiome is highly consolidated, with key players strategizing to capture majority of the market. Prominent players in the market are Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), OptiBiotix Health Plc (UK), Ferring Pharmaceuticals (Switzerland), Synlogic, Inc. (US), Second Genome, Inc. (US), Vedanta Biosciences, Inc.  (US),  YSOPIA Bioscience (France), FlightPath Biosciences, Inc. (US), Finch Therapeutics Group, Inc. (US), AOBiome Therapeutics (US), BioGaia (Sweden), Quantbiome, Inc. (dba Ombre) (US), Viome Life Sciences, Inc. (US), BIOHM Health (US), DayTwo (US), Atlas Biomed (UK), Bione Ventures Private Limited (India), Luxia Scientific (France), Metabiomics (US), Sun Genomics (US), Seed Health (US), and Gnubiotics Sciences (Switzerland).

Different Growth Strategies Adopted by Them:

These include product launches, contracts, partnerships, mergers and acquisitions, and new product development activities to further expand their presence in the human microbiome market.

Seres Therapeutics, Inc. (US)

The goal of Seres therapies is to create microbiome therapies to cure dysbiosis-related illnesses. The company has a robust pipeline of drugs in different stages of development, such as SER-287, which is being developed for the treatment of inflammatory bowel disease (IBD), and SER-109, which is intended to treat recurrent Clostridium difficile infection (CDI).

Seres Therapeutics' cutting-edge technological platform, which integrates bioinformatics, machine learning, and high-throughput DNA sequencing to find possible treatment candidates from the human microbiome, is another aspect that helps explain the company's dominance in the microbiome sector. With the help of this platform, the business may create tailored treatments meant to enhance patient outcomes and return the microbiome to its natural equilibrium.

Enterome (France)

Enterome's creative approach to creating microbiome-based medicines and diagnostics has made it a major participant in the human microbiome market. It is creating a series of diagnostic tests based on the microbiota. Microbial biomarkers are used in these tests to help diagnose and track a number of conditions, such as liver disorders, colon cancer, and inflammatory bowel disease.

To further enhance its R&D endeavors, Enterome has also formed a number of strategic alliances. For instance, the business and Takeda Pharmaceuticals have been working together since 2016 to develop microbiome-based medicines for the management of inflammatory bowel disease. The business and Nestlé Health Science collaborated in 2022 to create treatments and diagnostics based on the microbiome.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

4D pharma plc (UK)

Because of its creative approach to the development of microbiome-based treatments, 4D Pharma Plc is one of the major participants in the human microbiome market. Utilizing a proprietary platform technology known as MicroRx, the business is able to recognize, separate, and cultivate live bacteria from the gut microbiome. Through the process of identifying and isolating helpful bacteria with therapeutic properties, this approach allows the company to create accurate and focused medicines for particular ailments.

Furthermore, 4D Pharma is developing a robust portfolio of microbiome-based treatments at different phases of development, including Phase II and Phase III clinical trials to treat diseases like asthma, cancer, and irritable bowel syndrome. In addition, the company collaborates with major pharmaceutical companies such as MSD and AstraZeneca, which provides it with access to their expertise and resources.

Geographical Growth Dynamics:

Asia Pacific: The fastest-growing region in the human microbiome market.

The Asia Pacific human microbiome market is projected to grow at the highest CAGR during the forecast period, mainly due to increasing awareness of the importance of the microbiome in health and disease, the rising demand for personalized medicine, and advancements in sequencing technologies. The Asian market has also garnered significant attention from global players due to the increased focus on preventative healthcare and personalized medicine, driving the demand for human microbiomes.

Air Quality Monitoring System Market: Key Players Operating Globally

Overview of This Study:

This research employed a large number of primary and secondary sources. In order to determine the segmentation kinds, industry trends, major players, competitive landscape, important market dynamics, and major player strategies, the research procedure entailed analyzing a variety of industry-affecting aspects.

Global Growth Driving Factors:

The market is expected to grow as a result of rising global air pollution expenditures, government regulations governing efficient air pollution monitoring and control, rising public-private funding for efficient air pollution monitoring, rising public awareness of the negative effects of air pollution on the environment and human health, and expanding government initiatives supporting the growth of environmentally friendly industries.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=183784537

Projected Surge in Revenue Generation:

With a predicted revenue of $4.9 billion in 2023, the global market for air quality monitoring systems is expected to rise at a compound annual growth rate (CAGR) of 7.0% to reach $6.9 billion by 2028.

Leading Players:

As of 2022, the air quality monitoring systems market was dominated by Thermo Fisher Scientific (US), 3M (US), Siemens (Germany), Teledyne Technologies (US), GE Healthcare (US), Emerson Electric Company (US), Honeywell International Inc (US), HORIBA, Ltd. (Japan), Merck KGaA (Germany), and TSI Incorporated (US), among others.

Different Growth Strategies Adopted by Them:

These include product launches, contracts, partnerships, mergers and acquisitions, and new product development activities to further expand their presence in the air quality monitoring systems market.

Thermo Fisher Scientific (US)

One of the top suppliers in the worldwide market for air quality monitoring systems is Thermo Fisher Scientific (US). The primary reason for its substantial market share is its extensive product line and widespread geographic reach over important areas like North America, Europe, the APAC region, and Africa. Thermo Fisher concentrates on intensive research and development as well as ongoing product development. Its broad range of products includes gas analyzers, air samplers, monitoring systems, particle matter monitors, probes, and other accessories. Thermo Scientific AerosolSense Sampler, a surveillance tool for in-air viruses, including SARS-CoV-2, was introduced by the business in March 2021.

Among the other products that have been introduced are the TSQ 9000 triple quadrupole GC-MS systems, the SOLA iQ total sulfur analyzer, the TriPLus 500 gas chromatography headspace autosampler, and the Orbitrap exploris GC 240 MS and GC-MS. Because their products are produced in compliance with international safety standards, the company is a market leader.

Siemens AG (Germany)

Siemens AG, a German company, holds a prominent position in the worldwide market for air quality monitoring systems due to its robust R&D capabilities and extensive geographic reach. With a strong sales and distribution network spanning over 190 nations, Siemens is present throughout Europe, the Americas, Asia-Pacific, the Middle East, and Africa. With about 285 significant production and manufacturing sites spread out across the globe, the corporation boasts a strong manufacturing base. It is anticipated that a broad product offering and ongoing product development as a result of large investments in noteworthy R&D projects will bolster its position in the AQM market.

Siemens' Symaro line of air quality sensors, which are utilized for demand-controlled ventilation, has helped the company establish a significant foothold in the CO2 and O2 measurement market. It is anticipated that Siemen will considerably grow its market share over the course of the projected period thanks to its strong industry presence and excellent brand recognition in the AQM market.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=183784537

Geographical Growth Dynamics:

Over the course of the forecast period, the air quality monitoring system industry is anticipated to grow at the fastest rate in the Asia Pacific region.

Over the course of the forecast period, the air quality monitoring system market is anticipated to grow at the fastest rate in the Asia-Pacific region. The region's high compound annual growth rate (CAGR) can be attributed to a number of factors, including rising air quality monitoring spending by regional governments, the increasing adoption of advanced environmental monitoring technologies, and the modernization of public and industrial infrastructure due to rising middle-class disposable income and rising GDPs of Asian countries.

Pipette Calibrators Market: Role of Leading Companies in Global Growth

Overview of This Study:

Analyzing the major market dynamics—drivers, opportunities, challenges, restrictions, and key player strategies—is the study's goal. The competitive landscape of the pipette calibrators market can be used to track company developments, including product launches, acquisitions, agreements, and partnerships with leading players, as well as to analyze market players on a variety of parameters within the broad categories of business and product strategy. Two methods were employed to estimate the market size: top-down and bottom-up. The market split and data triangulation were used to estimate the market size of the various segments and subsegments.

Global Growth Driving Factors:

Industry trends, pricing analysis, patent analysis, conference and webinar materials, important stakeholders, and market purchasing behavior are all included in the latest research study. The expanding need for pipettes in research facilities, the increased use of portable handheld calibration equipment, and the use of cloud-based calibration management are all factors contributing to the market's expansion. The existence of substitute straightforward approaches or strategies, however, may limit this market's expansion.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12158123

Projected Surge in Revenue Generation:

The global pipette calibrators market in terms of revenue was estimated to be worth $286 million in 2024 and is poised to reach $391 million by 2029, growing at a CAGR of 6.5% from 2024 to 2029.

Leading Players:

The pipette calibrators market is consolidated and is dominated by few players. The major players operating in this market are METTLER TOLEDO (US), Sartorius AG (Germany), A&D Company, Limited (Japan), and Advanced Instruments (US).

Different Growth Strategies Adopted by Them:

These include product launches, contracts, partnerships, mergers and acquisitions, and new product development activities to further expand their presence in the pipette calibrators market.

METTLER TOLEDO (US)

In 2022, METTLER TOLEDO (US) will hold a dominant position in the pipette calibrators industry. The company is well-established in over 40 nations and sells its products in over 140 countries, mostly in the pipette calibrators sector. The company's clientele is geographically broad and purchases its items. It keeps refining its global supply network, which contributes to maintaining product availability. It is anticipated that this will assist the business in holding onto its market share.

SARTORIUS AG (GERMANY)

In terms of pipette calibrators, Sartorius AG (Germany) ranked second in 2022. The company's wide range of products is principally responsible for its dominant market position. The company provides a large selection of pipette calibrators, including software and systems. In addition, the company's robust customer base is mostly due to its wide regional presence. Furthermore, the corporation receives approximately 64.3% of its sales from important markets including the Americas and EMEA. Furthermore, Sartorius stands out from its rivals because to the depth of its product offering.

A&D COMPANY, LIMITED (JAPAN)

In 2022, A&D Company, Limited, a Japanese company, ranked third in the pipette calibrators market. The Measurement and Weighing Instruments division of A&D Company handles the pipette calibrators business, which takes care of pipette testing and calibration requirements. Japan provides the corporation with 71% of its revenue.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=12158123

Geographical Growth Dynamics:

North America dominates the global pipette calibrators market.

The pipette calibrators market has been divided into four regions: North America, Europe, Asia Pacific, and Rest of the World. The availability of cutting-edge goods and the expansion of monoclonal antibody research in the biopharmaceutical industries are driving the North American market. Over the course of the projection period, the Asia Pacific segment is expected to achieve the greatest CAGR. Some of the key reasons propelling the expansion of this regional market are the increase in pharmaceutical research outsourcing, particularly in drug trials, and the advancement of life sciences research throughout Asian nations.

Respiratory Care Devices Market: Revenue Growth Predictions by 2028

Global Growth Driving Factors:

The number of patients with respiratory conditions like COPD and asthma, the rise in the number of overweight and obese people, and the rising number of preterm births are the main factors driving this market's growth. Over the past 20 years, preterm birth rates have increased globally. There is an increased risk of preterm delivery when a woman becomes pregnant at an inappropriate age, usually over 40 and under 20.

Maternal health issues such as diabetes, high blood pressure, and extensive use of infertility treatments are contributing factors to preterm births. In addition, women from particular ethnic groups have a genetic predisposition to preterm births. For example, preterm births are highly likely among African-American and Hispanic populations in the United States. Preterm birth rates are further increased by obesity and smoking during pregnancy.

Market Size Estimation:

After data triangulation from two distinct approaches, the market size for respiratory care devices was determined, as will be discussed below. Based on the degree of assumptions made in each approach, a weighted average of all approaches was determined after each one.

Revenue Growth Dynamics:

Revenue from respiratory care devices was projected to reach $21.8 billion globally in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 7.8% to $31.8 billion by 2028.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=368

Objectives of this Study:

# To define, describe, segment, and forecast the global respiratory care devices market on the basis of product, disease indications, end user, and region.

# To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges).

# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall respiratory care devices market.

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players functioning in this market.

# To forecast the size of the respiratory care devices market in five main regions as well as country-wise segmentation (North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa).

# To profile key players in the respiratory care devices market and comprehensively analyze their core competencies and market shares.

# To track and analyze competitive developments such as acquisitions; product launches; expansions; collaborations, partnerships, and agreements of the leading players in the respiratory care devices market.

Opportunity: Point-of-care Diagnostics

At or close to the location of patient care, point-of-care (POC) testing is carried out. The main factors creating a niche market opportunity for POC devices in respiratory diagnostics are improvements in test accuracy and the growing number of diagnostic tests available for various conditions.

Growing patient self-testing is one of the main factors propelling the POC respiratory disease diagnostics market. In the upcoming years, technological developments that are facilitating microfabrication processes and devising miniaturization are anticipated to bolster the trend of POC testing and the treatment of respiratory disorders. Government agencies in developed and developing nations alike have realized that POC technology offers a perfect opportunity to grow public healthcare networks and meet patients' unmet medical needs. Furthermore, POC testing is becoming more and more preferred as the number of qualified technicians in the centralized system declines.

Challenge: Lack of patient compliance

A major factor impeding the market's growth is patient noncompliance with CPAP therapy. Patients with respiratory and sleep-related diseases have historically had trouble adhering to their treatment plans, primarily because of a variety of problems like comfort and cost.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=368

Another reason why patients are unwilling to pay for treatment is the extremely low reimbursement rates in regions like Asia (China and India) and the Rest of the World. It is discovered that non-compliance is more common among CPAP users. According to studies, the claustrophobic nature of CPAP therapy makes it difficult for between 30% and 50% of patients to continue receiving it. According to another survey, discomfort from the masks or airflow was the main cause of non-compliance with treatment, with approximately half of CPAP patients stopping their device within 1-3 weeks of starting to use it.

Geographical Growth Dynamics:

The respiratory care devices market was dominated by the North American segment.

The regions of North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa comprise the global respiratory care devices market. The respiratory care devices market was dominated by North America in 2022. The North American market for respiratory care devices is anticipated to grow as a result of the region's sophisticated healthcare infrastructure and high healthcare spending. Throughout the forecast period, the US's high prevalence of asthma is anticipated to fuel demand for respiratory care devices.

Global Leading Players:

The global respiratory care devices market is dominated by a few globally established players such as Koninklijke Philips N.V. (Netherlands), General Electric Healthcare (US), ResMed Inc. (US), Fisher & Paykel Healthcare Corporation Limited (New Zealand), and Medtronic plc (Ireland). Major players adopt growth strategies to expand their geographical presence and garner higher shares in the global market.

Growth Strategies Opted by Them:

To stay competitive and grow their market share, these businesses are mainly focused on tactics like partnerships, product launches, acquisitions, agreements, collaborations, and expansions.

Read the Detailed Report, Here@
https://www.marketsandmarkets.com/Market-Reports/respiratory-care-368.html